Lupin Limited (Lupin), global pharmaceutical company, announced today the launch of Meloxicam Capsules, 5 mg, and 10 mg, having received an approval from the United States Food and Drug Administration.

Meloxicam Capsules, 5 mg and 10 mg, is the generic equivalent of Vivlodex Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc., and indicated for management of osteoarthritis (OA) pain.

Meloxicam Capsules (RLD: Vivlodex) had an annual sales of approximately USD 11 million in the U.S. (IQVIA MAT October 2020).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.